top of page

Free Biopharma Daily Stock Updates - 02/14/22

$XBI $91.81 | -1.7%

 

Covid Updates

$NVAX -11.4% Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland. source


$VERU -4.6% Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned. source


$ABCL -1.5% AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19. source



Pipeline Updates

$ARVN -0.4% Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting source


$IBRX -3.5% ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer source


$AVEO -2.0% AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma source


$AZN -0.9% Lynparza plus abiraterone reduced risk of disease progression by 34% vs. standard-of-care in 1st-line metastatic castration-resistant prostate cancer source


$LRMR +0.2% Larimar Therapeutics Provides Update on CTI-1601 Clinical Program source


$RNAZ +0.7% TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio. source


$UBX +7.1% UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease. source


$KNTE -5.6% Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting. source


$AXLA -4.6% Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH. source


$CLNN -2.6% Clene Nanomedicine Provides Clinical Program Update. source


$DNLI +0.08% Denali has now received a formal clinical hold letter for DNL919 (previously informed 1/12/22) and is moving forward to address the FDA’s observations. source


$BHVN +2.2% Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea. source


$RGNX 0.0% REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery. source


$EYPT -2.4% EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD. source



Business Updates

$VERA +3.1% Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares source

$MBRX -2.7% Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development. source


$LCTX 0.0% Compensation Committee of the Board of Directors of Lineage Cell Therapeutics, Inc. (the “Company”) approved restricted stock units awards (“RSUs”) for an aggregate of 694,424 of the Company’s common shares, to certain of its employees. source


$BDSI +52.8% & $COLL +13.1% Collegium to Acquire BioDelivery Sciences in an All-Cash Deal. source


 

Posted by FS/JM

0 comments
bottom of page